Advertisement
Organisation › Details
Novartis Deutschland GmbH
Start | 1997-01-01 existent | |
Group | Novartis (Group) | |
Industry | pharmaceutical | |
Region | Germany (town unspecified) | |
Country | Germany | |
City | n. a. | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Record changed: 2023-12-30 |
Advertisement
More documents for Novartis (Group)
- [1] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
- [2] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
- [3] Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam....
- [4] Shanghai Argo Biopharmaceutical Co., Ltd.. (1/7/24). "Press Release: Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis". Shanghai....
- [5] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
- [6] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
- [7] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
- [8] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [9] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
- [10] Intellegens Ltd.. (8/30/23). "Press Release: Intellegens and CPI Awarded £1.6m Innovate UK Grant to Advance Manufacture of Oligonucleotide Therapeutics with Machine Learning". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top